Hinsley, Samantha
Walker, Katrina http://orcid.org/0000-0001-6922-9100
Sherratt, Debbie
Bailey, Lucy
Reed, Sadie
Flanagan, Louise
McKee, Sophie
Brudenell Straw, Fiona
Dawkins, Bryony
Meads, David
Auner, Holger W.
Kaiser, Martin F.
Cook, Mark
Brown, Sarah
Cook, Gordon
,
Funding for this research was provided by:
Myeloma UK
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 8 August 2018
Accepted: 12 September 2020
First Online: 2 October 2020
Ethics approval and consent to participate
: The trial has received national research ethics approval from the NHS National Research Ethics Service North West, Liverpool East (REC Number: 15/NW/0416). All patients provide written informed consent prior to randomisation in to the trial.
: Not applicable.
: SH, KW, DS, LB, SR, LF, SM, FBS, BD, DM and SB declare they have no competing interests. HWA declares research support from Amgen, consultancy fees and honoraria from Amgen, Takeda, and Novartis, and Karyopharm. MFK has served as a consultant and received honoraria from Celgene, Takeda, Amgen, Chugai, BMS, and Janssen, and has received research funding from Celgene. MC declares honoraria and travel fees from Janssen, Celgene, Takeda, Amgen and Chugai and has received research support from Celgene, CRUK and Janssen. GC has served as a consultant and speaker for Takeda, Amgen, Janssen and Seattle Genetics and has received research funding from Takeda and Celgene. The trial is sponsored by the University of Leeds (contact details accessible via the trial registration, ISRCTN58227268).